Status:
TERMINATED
Hip Fracture Surgery and Oral Nutritional Supplements
Lead Sponsor:
Société des Produits Nestlé (SPN)
Conditions:
Hip Fracture
Eligibility:
All Genders
70+ years
Phase:
PHASE3
Brief Summary
Senior hip fracture patients are the most vulnerable to malnutrition and protein deficiency. Low protein intake, like vitamin D deficiency, contribute to an increased risk for hip fracture. Notably, s...
Eligibility Criteria
Inclusion
- Age (70+);
- Had an acute hip fracture and surgical treatment
- Able to walk at least 3 meters without assistance of another person, with or without a walking aid other than a wheeled walker prior to hip fracture MMSE \>=18 (proxy will be informed in addition if MMS-score ≤ 24)
- Able to perform the SPPB at baseline
- No prior hip fracture
- Patient (and/or his/her legal representatives/relatives) understands the study procedure, alternative treatments available and risks involved with the study, and voluntarily agrees to participate by giving his/her (or his/her legal representative's/relatives) written informed consent.
Exclusion
- Baseline visit can not be performed between the second and tenth postoperative day.
- Milk protein allergy
- Patients with conservative treatment for hip fracture
- Serum calcium adjusted for albumin of \> 2.6 mmol/L
- Pathologic fracture in the last year (except for fractures due to osteoporosis)
- Chemo therapy / Radiation /antihormonal therapy due to cancer in the last year
- Treatment which has an effect on calcium metabolism (e.g. PTH, calcitonin, chronic cortisone intake \> 5mg/day in the last 12 months (except for inhalation and sporadic infiltration))
- Oral vitamin D intake of more than 1000 IU per day during the last 3 months before the study
- Unwilling to stop multi-vitamin, calcium supplementation, and vitamin D supplementation during the trial (maximal calcium supplement intake 250mg/d; no additional vitamin D supplementation). We will inform the treating physician that we initiated vitamin D supplementation as standard of care.
- Severe visual or hearing impairment
- Unwilling or unable to take study medication
- Diseases with a risk of recurrent falling (e.g. Parkinson's disease/syndrome, Hemiplegia after stroke, symptomatic stenosis of the spinal canal, polyneuropathy, epilepsy, recurring vertigo, recurring syncope) BMI ≥ 40
- Estimated creatinine clearance \< 15 ml/min (estimated Creatinine Clearance cockcroft and Gault)
- Malabsorption syndrome (celiac diseases, inflammatory bowel disease, hepatic and/or pancreas dysfunction)
- Diseases that may enhance serum calcium: sarcoidosis, lymphoma, primary hyperparathyroidism
- Kidney stone in the last 10 years
- Patient heavily consumes alcohol containing products defined as greater than (\>) 3 drinks (beer, wine, or distilled spirits) of alcoholic beverages per day.
- Patients who are planning a stay in a "sunny" location (e.g. winter sun resort) for more than one month during the trial
- Medication which has an effect on serum 25-hydroxyvitamin D level (e.g. certain anticonvulsants (e.g. Phenobarbital, Carbamazepin, Phenytoin) M. Paget (Ostitis deformans)
- Inflammatory arthritis (e.g. rheumatoid arthritis, reiter syndrome, psoriasis arthritis)
- Uncontrolled metabolic conditions, or psychiatric conditions that might make tolerance or evaluation of the feeding formula difficult
- Severe acute and/or chronic disease that makes the performance of the study assessments impossible (e.g. severe infection/sepsis, myocardial infarction, heart failure, respiratory failure or renal failure);
- Patient is taking peripherally acting anti-adiposity drugs (e.g. Xenical®, formoline L112®, (Acomplia®))
- Patients taking protein supplements (\>15g per serving more than once a week) or are unwilling to stop any protein supplements during the trial Participation in a study in the last 6 month, except for studies without drug-application, or any influence of the study-medication can be excluded
- Patient is unlikely to adhere to the study procedures, to keep appointments, or is planning to relocate during the study.
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2013
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01505985
Start Date
January 1 2012
End Date
September 1 2013
Last Update
November 25 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Zurich,Dept. of Rheumatology and Institute of Physical Medicine,
Zurich, Switzerland, 8091